WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

China Stocks Slump; Tech Earnings Surge Ahead of US Payrolls https://money.usnews.com/investing/news/articles/2024-02-01/asian-shares-buoyed-by-us-tech-bounce-payrolls-in-focus .... Shares in drug research and development group WuXi AppTec went limit down in Shanghai and dropped 20% in Hong Kong as its mention in a U.S. bill aimed at restricting access to Americans' genetic data again raised geopolitical concerns. "The tension between the U.S. and China seems not dissipating," said Saxo's chief China strategist, Redmond Wong, while investors are also growing impatient at the lack of big-ticket stimulus to shore up demand and confidence. ... ...da half bei der AppTec nicht mal die Ankündigung eines Aktienrückkaufprogramms. Sind beide ordentlich betroffen.

So sehen normalerweise Pleite Kandidaten aus. Diese Riesenabschläge sind heftig.

Und wieder ein drauf

Und?

https://www.fiercepharma.com/pharma/wuxi-biologics-plays-defense-after-draft-bill-brands-certain-chinese-biopharmas-security

N bis hen beruhigen lassen dann zugreifen

https://www.yicaiglobal.com/news/fact-check-wuxi-biologics-plunges-on-concerns-about-new-us-bill

https://www.prnewswire.com/news-releases/wuxi-biologics-announces-research-service-agreement-with-biontech-on-discovering-investigational-monoclonal-antibodies-for-developing-next-generation-therapeutic-product-candidates-302031587.html

https://www.fiercepharma.com/pharma/wuxi-biologics-stock-plummets-crdmo-trims-400m-revenue-projection

WUXI BIO: Umsatz und Gewinn unerwartet durch D- und M-Ende beeinträchtigt; GPM und Wachstum werden im Jahr 2023 voraussichtlich mit Gegenwind konfrontiert sein http://www.aastocks.com/en/mobile/news.aspx?newsid=NOW.1311318&newstype=61&newssource=AAFN

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1302977/

https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a231020.pdf UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF WUXI XDC CAYMAN INC.

WuXi Biologics Reports Solid 2023 Interim Results https://finance.yahoo.com/news/wuxi-biologics-reports-solid-2023-123000711.html Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth, Strong Momentum Continued Non-COVID Late-phase And Commercial Manufacturing Revenue Grew by 130.3% Y-o-Y "R" in CRDMO Accelerated to Extend Partnerships with Pharma Clients, Milestone Revenue Approximated US$60 Million Positive Free Cash Flow to Support Sustainable Growth Total Backlog Amounted to US$20,108 Million ...

https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/wuxi-biologics-cayman-incs-hkg2269-fundamentals-look-pretty

WuXi Biologics Hatches New Baby With ADC Drug Unit IPO https://seekingalpha.com/article/4618020-wuxi-biologics-hatches-new-baby-with-adc-drug-unit-ipo Summary • The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. • WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provider of contract services for bioconjugates such as antibody drug conjugates (ADCs). • The global market ADC drugs is expected to grow by 30% annually between 2022 and 2030. ...

WuXi Biologics: Spin-Off And New Projects In The Limelight (Rating Upgrade) https://seekingalpha.com/article/4618035-wuxi-biologics-spin-off-new-projects-in-limelight-rating-upgrade Summary • I have a favorable opinion of WuXi Biologics' planned spin-off, which could re-rate its valuations in a positive manner and help to accelerate the future growth of the spun-off business. • WXXWY's disclosures at its recent Investor Day regarding new project count have negative read-throughs for its near-term top-line growth prospects. • I upgrade my investment rating for WuXi Biologics to a Hold following a review of its spin-off plans, but WXXWY isn't a Buy as its business outlook is still unfavorable. ...